+Compare
NVAX
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
644.7M

NVAX Price Prediction, Novavax AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for NVAX with price predictions
08:00 PM EDT Jun 08, 2023

NVAX's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for NVAX turned positive on June 07, 2023. Looking at past instances where NVAX's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where NVAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 08, 2023. You may want to consider a long position or call options on NVAX as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

NVAX moved below its 50-day moving average on June 06, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on May 26, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NVAX broke above its upper Bollinger Band on May 09, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (49.505) is normal, around the industry mean (25.340). P/E Ratio (0.000) is within average values for comparable stocks, (123.530). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.381). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (0.439) is also within normal values, averaging (310.379).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I. Advisor
published Earnings

NVAX is expected to report earnings to fall 58.94% to -139 cents per share on August 03

Novavax NVAX Stock Earnings Reports
Q2'23
Est.
$-1.40
Q1'23
Beat
by $0.01
Q4'22
Missed
by $1.09
Q3'22
Missed
by $3.78
Q2'22
Missed
by $10.17
The last earnings report on May 09 showed earnings per share of -341 cents, beating the estimate of -342 cents. With 5.50M shares outstanding, the current market capitalization sits at 644.70M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.14B. The market cap for tickers in the group ranges from 402 to 354.23B. NONOF holds the highest valuation in this group at 354.23B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 36%. ONPH experienced the highest price growth at 129%, while BLPH experienced the biggest fall at -90%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 55
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in development of novel recombinant vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
21 Firstfield Road
Phone
+1 240 268-2000
Employees
1992
Web
https://www.novavax.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LFGTX21.550.15
+0.70%
Lord Abbett Focused Growth R5
BTMKX14.67-0.02
-0.14%
iShares MSCI EAFE Intl Idx K
ABECX20.12-0.05
-0.25%
American Beacon The London Co Inc Eq C
ARYWX11.33-0.06
-0.53%
American Century Global Real Estate R
VSFIX23.00-0.13
-0.56%
Federated Hermes Clover Small Value IS

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-2.86%
CRSP - NVAX
53%
Loosely correlated
-2.16%
BEAM - NVAX
52%
Loosely correlated
-3.71%
OCGN - NVAX
51%
Loosely correlated
-1.14%
INO - NVAX
51%
Loosely correlated
-5.14%
EDIT - NVAX
50%
Loosely correlated
+0.73%
More